Physician profile
Tracy E Estridge
NPI 1619252178
$6,004.61
in general payments reported to CMS, 2019-2025
56 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $605 · 2022: $1,136 · 2023: $1,454 · 2024: $1,307 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,164 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,163.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $612.79 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Biotech, INC. | $511.54 | 2021-2025 | Darzalex, Erleada, Tecvayli |
| Novartis Pharmaceuticals Corporation | $400.49 | 2021-2025 | |
| Pfizer INC. | $386.60 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $323.23 | 2021-2025 | Tagrisso, Calquence |
| Incyte Corporation | $306.64 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Seagen INC. | $232.57 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Celgene Corporation | $208.73 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Astellas Pharma US INC | $204.95 | 2021-2025 | Vyloy, Padcev |
| Abbvie INC. | $200.45 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $186.41 | 2023-2025 | Libtayo |
| Amgen INC. | $168.79 | 2021-2023 | Blincyto |
| Daiichi Sankyo INC. | $166.49 | 2021-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $125.72 | 2022-2025 | Opdualag, Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $123.10 | 2021-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $118.62 | 2023-2025 | Tivdak, Epkinly |
| Eisai INC. | $117.85 | 2021-2025 | |
| Glaxosmithkline, LLC. | $109.61 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $100.63 | 2022-2025 | Fruzaqla, Iclusig |
| Rigel Pharmaceuticals, INC. | $96.65 | 2022-2024 | Tavalisse, Rezlidhia |
| Lilly USA, LLC | $74.56 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $71.24 | 2021-2023 | Imbruvica, Epkinly |
| Karyopharm Therapeutics INC. | $66.20 | 2021-2023 | Xpovio |
| Aveo Pharmaceuticals, INC. | $64.60 | 2022-2025 | |
| Gilead Sciences, INC. | $64.36 | 2024-2025 | |
| Genzyme Corporation | $59.78 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $55.34 | 2021-2025 | |
| Taiho Oncology, INC. | $51.91 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $46.50 | 2021-2023 | Tazverik |
| Coherus Oncology, INC. | $44.28 | 2022-2024 | |
| Puma Biotechnology, INC. | $43.61 | 2022-2025 | |
| Blueprint Medicines Corporation | $42.65 | 2024-2025 | Ayvakit |
| G1 Therapeutics, INC. | $41.09 | 2023 | Cosela |
| Adc Therapeutics America, INC. | $37.61 | 2023-2025 | |
| Boston Scientific Corporation | $37.11 | 2023 | Spaceoar Vue System - 10ml |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.48 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $34.16 | 2023-2024 | Monoferric |
| Genentech USA, INC. | $34.03 | 2023-2025 | Lunsumio, Polivy, Columvi |
| Kyowa Kirin, INC. | $31.66 | 2023 | Poteligeo |
| Emd Serono, INC. | $30.14 | 2022 | |
| Alexion Pharmaceuticals, INC. | $29.70 | 2021 | |
| Pharmaessentia USA Corporation | $29.51 | 2025 | Besremi |
| Morphosys, US INC. | $28.63 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $25.98 | 2025 | Pyrukynd |
| Stemline Therapeutics INC. | $25.94 | 2024 | Orserdu |
| Mirati Therapeutics, INC. | $23.99 | 2024 | Krazati |
| Clovis Oncology, INC. | $20.73 | 2021-2022 | |
| Beigene USA, INC. | $20.40 | 2025 | Brukinsa |
| Progenics Pharmaceuticals, INC. | $19.82 | 2024 | |
| Beone Medicines USA, INC. | $19.73 | 2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $18.84 | 2024 | |
| Cycle Pharmaceuticals INC | $17.39 | 2025 | Phyrago |
| Novocure INC. | $16.85 | 2022 | |
| Caris Mpi, INC. | $14.66 | 2025 | Mi Cancer Seek |
| Blue Earth Diagnostics | $14.50 | 2025 | Posluma |
| Array Biopharma INC | $8.77 | 2023 | Paxlovid, Mektovi, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Estridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.